Our results demonstrate that SPRY2-OE enhances c-CBL-mediated ubiquitination and degradation of FGFR1, thereby reducing FGF2-induced activation of PLCγ1 and of ERK in human GBM cells. The gene discussed is SPRY2; the disease is glioblastoma.